Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Authors:
- Kellie N. SmithKSKellie N. Smith
- Nicolas J. LlosaNLNicolas J. Llosa
- Tricia R. CottrellTCTricia R. Cottrell
- Nicholas SiegelNSNicholas Siegel
- Hongni FanHFHongni Fan
- Prerna SuriPSPrerna Suri
- Hok Yee ChanHCHok Yee Chan
- Haidan GuoHGHaidan Guo
- Teniola OkeTOTeniola Oke
- Anas H. AwanAAAnas H. Awan
- Franco VerdeFVFranco Verde
- Ludmila DanilovaLDLudmila Danilova
Open Access
- 11 February 2019
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 7 (1) , 40
Abstract
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mutational burden (TMB) also being explored with promising results, and mismatch-repair deficiency is approved for tumor site-agnostic disease. While tumors with high PD-L1 expression, high TMB, or mismatch repair deficiency respond well to checkpoint blockade, tumors with lower PD-L1 expression, lower mutational burdens, or mismatch repair proficiency respond much less frequently. Case presentation We studied two patients with unexpected responses to checkpoint blockade monotherapy: a patient with PD-L1-negative and low mutational burden NSCLC and one with mismatch repair proficient colorectal cancer (CRC), both of whom lack the biomarkers associated with response to checkpoint blockade, yet achieved durable clinical benefit. Both maintained T-cell responses in peripheral blood to oncogenic driver mutations – BRAF-N581I in the NSCLC and AKT1-E17K in the CRC – years after treatment initiation. Mutation-specific T cells were also found in the primary tumor and underwent dynamic perturbations in the periphery upon treatment. Conclusions These findings suggest that T cell responses to oncogenic driver mutations may be more prevalent than previously appreciated and could be harnessed in immunotherapeutic treatment, particularly for patients who lack the traditional biomarkers associated with response. Comprehensive studies are warranted to further delineate additional predictive biomarkers and populations of patients who may benefit from checkpoint blockade.Keywords
Funding Information
- National Cancer Institute (R01 CA203891, R01 CA121113)
- Cancer Research Institute (#)
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Commonwealth Foundation (#)
This publication has 25 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaJournal of Clinical Investigation, 2018
- Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection ToolAmerican Journal of Clinical Pathology, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Personalized genomic analyses for cancer mutation discovery and interpretationScience Translational Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and ImmunogenicityThe Journal of Immunology, 2013
- Using synthetic templates to design an unbiased multiplex PCR assayNature Communications, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012